Journal article
EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease
M Arbyn, S De Sanjosé, M Saraiya, M Sideri, J Palefsky, C Lacey, M Gillison, L Bruni, G Ronco, N Wentzensen, J Brotherton, YL Qiao, L Denny, J Bornstein, L Abramowitz, A Giuliano, M Tommasino, J Monsonego
International Journal of Cancer | WILEY | Published : 2012
DOI: 10.1002/ijc.27650
Abstract
The EUROGIN 2011 roadmap reviews the current burden of human papillomavirus (HPV)-related morbidity, as well as the evidence and potential practice recommendations regarding primary and secondary prevention and treatment of cancers and other disease associated with HPV infection. HPV infection causes ∼600,000 cases of cancer of the cervix, vulva, vagina, anus and oropharynx annually, as well as benign diseases such as genital warts and recurrent respiratory papillomatosis. Whereas the incidence of cervical cancer has been decreasing over recent decades, the incidence of anal and oropharyngeal carcinoma, for which there are no effective screening programs, has been rising over the last couple..
View full abstractGrants
Awarded by European Commission
Funding Acknowledgements
MA: Participation at Eurogin conference (Lisbon 2011) funded by organizers of the conference. SdS has an unrestricted grant from Merck and has had occasional grants for assistance to scientific meetings from GSK, MSD and Qiagen. MSi: consultancy with salary to IEO with the following companies: Qiagen, GSK, Sanofi Pasteur, MTM labs, Roche Diagnostics, Innogenetics. CL has acted as a consultant for SPMSD and received travel grants from SPMSD & GSK. MG: Merck (funding and consulting), GSK (consulting). JBr: investigator on an Australian Research Council Linkage Grant, for which CSL Biotherapies is a partner organization and was a chief investigator on a study of HPV prevalence in Australian women, which was funded by a grant from the Cooperative Research Centre for Aboriginal Health, as well as education grants in aid from GlaxoSmithKline and CSL Limited. LD has received honoraria from Merck and Glaxosmithkline for appearing on various speaker fora and has conducted research funded by both organizations. AG: Merck (Speaker Bureau, consult, grant funding), GSK (grant funding). JM has participated to Steering Committees at Merck and to the Advisory Board of Sanofi Pasteur MSD, Gen-Probe, Qiagen and Roche Diagnostics. Grant sponsors: Directorate of SANCO of the European Commission, Luxembourg, Grand-Duchy of Luxembourg [through the ECCG project (European Cooperation on Development and Implementation of Cancer Screening and Prevention Guidelines), the IARC, Lyon, France and through the EUROCHIP-3 Network (Istituto Nazionale dei Tumori, Milan, Italy)]. The Belgian Foundation Against Cancer (Brussels, Belgium). The 7th Framework Programme of DG Research of the European Commission (PREHDICT Project, coordinated by the Vrije Universiteit Amsterdam, the Netherlands), Grant number: 242061; the HPV-AHEAD Project (coordinated by IARC), Grant number: FP7-HEALTH-2011-282562. The Intramural Research Program of the National Cancer Institute (Bethesda, USA).